Inhibition of platelet-derived growth factor receptor tyrosine kinase by atrial natriuretic peptide

Midori Awazu

Research output: Contribution to journalArticle

9 Citations (Scopus)

Abstract

Atrial natriuretic peptide (ANP) is known to suppress platelet-derived growth factor (PDGF)-stimulated proliferation of rat cultured vascular smooth muscle cells. The present study examined whether ANP inhibits the PDGF receptor (PDGFR) tyrosine kinase activation, an initial event for PDGF cellular signaling. ANP reduced the in vive tyrosine phosphorylation of PDGFR stimulated by PDGF in a dose-dependent manner. This effect was not due to the reduction in PDGFR protein as detected by immunoblot analysis. 8-Bromocyclic GMP, a membrane- permeable 3',5'-cyclic monophosphate (cGMP) derivative, mimicked the action of ANP. HS-142-1, an antagonist for guanylate cyclase A (GC-A) and B, co-incubated with ANP, restored the PDGFinduced PDGFR autophosphotylation. The effect of ANP was also observed in the presence of a protein tyrosine phosphatase inhibitor, sodium orthovanadate. To confirm that ANP exerts its action by inhibiting protein tyrosine kinase (PTK), an in vitro kinase assay was performed. Cyclic GMP inhibited PTK activity of PDGFR partially purified by lectin affinity chromatography. In contrast, PTK activity in immobilized PDGFR immunocomplexes was not inhibited by cGMP. However, exogenous cGMP dependent protein kinase (PKG) reduced the PTK activity in the presence of cGMP. These results demonstrate that ANP suppresses PDGFR PTK through GC-A probably by activating PKG. This may be an important mechanism by which ANP exerts its anti-proliferative action antagonizing PDGF.

Original languageEnglish
Pages (from-to)356-362
Number of pages7
JournalKidney International
Volume52
Issue number2
Publication statusPublished - 1997

Fingerprint

Atrial Natriuretic Factor
Platelet-Derived Growth Factor Receptors
Platelet-Derived Growth Factor
Protein-Tyrosine Kinases
PDGF receptor tyrosine kinase
Cyclic GMP-Dependent Protein Kinases
Protein Tyrosine Phosphatases
Vanadates
Guanylate Cyclase
Cyclic GMP
Receptor Protein-Tyrosine Kinases
Vascular Smooth Muscle
Affinity Chromatography
Lectins
Smooth Muscle Myocytes
Tyrosine
Phosphotransferases
Sodium
Phosphorylation
Membranes

Keywords

  • Atherosclerosis
  • Atrial natri-uretic peptide
  • Growth factor
  • Hypertension
  • Platelet-derived growth factor
  • Tyrosine kinase

ASJC Scopus subject areas

  • Nephrology

Cite this

Inhibition of platelet-derived growth factor receptor tyrosine kinase by atrial natriuretic peptide. / Awazu, Midori.

In: Kidney International, Vol. 52, No. 2, 1997, p. 356-362.

Research output: Contribution to journalArticle

@article{ec317dfdb3f7421ca6d5f81cc5125c84,
title = "Inhibition of platelet-derived growth factor receptor tyrosine kinase by atrial natriuretic peptide",
abstract = "Atrial natriuretic peptide (ANP) is known to suppress platelet-derived growth factor (PDGF)-stimulated proliferation of rat cultured vascular smooth muscle cells. The present study examined whether ANP inhibits the PDGF receptor (PDGFR) tyrosine kinase activation, an initial event for PDGF cellular signaling. ANP reduced the in vive tyrosine phosphorylation of PDGFR stimulated by PDGF in a dose-dependent manner. This effect was not due to the reduction in PDGFR protein as detected by immunoblot analysis. 8-Bromocyclic GMP, a membrane- permeable 3',5'-cyclic monophosphate (cGMP) derivative, mimicked the action of ANP. HS-142-1, an antagonist for guanylate cyclase A (GC-A) and B, co-incubated with ANP, restored the PDGFinduced PDGFR autophosphotylation. The effect of ANP was also observed in the presence of a protein tyrosine phosphatase inhibitor, sodium orthovanadate. To confirm that ANP exerts its action by inhibiting protein tyrosine kinase (PTK), an in vitro kinase assay was performed. Cyclic GMP inhibited PTK activity of PDGFR partially purified by lectin affinity chromatography. In contrast, PTK activity in immobilized PDGFR immunocomplexes was not inhibited by cGMP. However, exogenous cGMP dependent protein kinase (PKG) reduced the PTK activity in the presence of cGMP. These results demonstrate that ANP suppresses PDGFR PTK through GC-A probably by activating PKG. This may be an important mechanism by which ANP exerts its anti-proliferative action antagonizing PDGF.",
keywords = "Atherosclerosis, Atrial natri-uretic peptide, Growth factor, Hypertension, Platelet-derived growth factor, Tyrosine kinase",
author = "Midori Awazu",
year = "1997",
language = "English",
volume = "52",
pages = "356--362",
journal = "Kidney International",
issn = "0085-2538",
publisher = "Nature Publishing Group",
number = "2",

}

TY - JOUR

T1 - Inhibition of platelet-derived growth factor receptor tyrosine kinase by atrial natriuretic peptide

AU - Awazu, Midori

PY - 1997

Y1 - 1997

N2 - Atrial natriuretic peptide (ANP) is known to suppress platelet-derived growth factor (PDGF)-stimulated proliferation of rat cultured vascular smooth muscle cells. The present study examined whether ANP inhibits the PDGF receptor (PDGFR) tyrosine kinase activation, an initial event for PDGF cellular signaling. ANP reduced the in vive tyrosine phosphorylation of PDGFR stimulated by PDGF in a dose-dependent manner. This effect was not due to the reduction in PDGFR protein as detected by immunoblot analysis. 8-Bromocyclic GMP, a membrane- permeable 3',5'-cyclic monophosphate (cGMP) derivative, mimicked the action of ANP. HS-142-1, an antagonist for guanylate cyclase A (GC-A) and B, co-incubated with ANP, restored the PDGFinduced PDGFR autophosphotylation. The effect of ANP was also observed in the presence of a protein tyrosine phosphatase inhibitor, sodium orthovanadate. To confirm that ANP exerts its action by inhibiting protein tyrosine kinase (PTK), an in vitro kinase assay was performed. Cyclic GMP inhibited PTK activity of PDGFR partially purified by lectin affinity chromatography. In contrast, PTK activity in immobilized PDGFR immunocomplexes was not inhibited by cGMP. However, exogenous cGMP dependent protein kinase (PKG) reduced the PTK activity in the presence of cGMP. These results demonstrate that ANP suppresses PDGFR PTK through GC-A probably by activating PKG. This may be an important mechanism by which ANP exerts its anti-proliferative action antagonizing PDGF.

AB - Atrial natriuretic peptide (ANP) is known to suppress platelet-derived growth factor (PDGF)-stimulated proliferation of rat cultured vascular smooth muscle cells. The present study examined whether ANP inhibits the PDGF receptor (PDGFR) tyrosine kinase activation, an initial event for PDGF cellular signaling. ANP reduced the in vive tyrosine phosphorylation of PDGFR stimulated by PDGF in a dose-dependent manner. This effect was not due to the reduction in PDGFR protein as detected by immunoblot analysis. 8-Bromocyclic GMP, a membrane- permeable 3',5'-cyclic monophosphate (cGMP) derivative, mimicked the action of ANP. HS-142-1, an antagonist for guanylate cyclase A (GC-A) and B, co-incubated with ANP, restored the PDGFinduced PDGFR autophosphotylation. The effect of ANP was also observed in the presence of a protein tyrosine phosphatase inhibitor, sodium orthovanadate. To confirm that ANP exerts its action by inhibiting protein tyrosine kinase (PTK), an in vitro kinase assay was performed. Cyclic GMP inhibited PTK activity of PDGFR partially purified by lectin affinity chromatography. In contrast, PTK activity in immobilized PDGFR immunocomplexes was not inhibited by cGMP. However, exogenous cGMP dependent protein kinase (PKG) reduced the PTK activity in the presence of cGMP. These results demonstrate that ANP suppresses PDGFR PTK through GC-A probably by activating PKG. This may be an important mechanism by which ANP exerts its anti-proliferative action antagonizing PDGF.

KW - Atherosclerosis

KW - Atrial natri-uretic peptide

KW - Growth factor

KW - Hypertension

KW - Platelet-derived growth factor

KW - Tyrosine kinase

UR - http://www.scopus.com/inward/record.url?scp=0030748280&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=0030748280&partnerID=8YFLogxK

M3 - Article

C2 - 9263990

AN - SCOPUS:0030748280

VL - 52

SP - 356

EP - 362

JO - Kidney International

JF - Kidney International

SN - 0085-2538

IS - 2

ER -